Response rates and survival times for cats with lymphoma treated with the University of Wisconsin-Madison chemotherapy protocol: 38 cases (1996-2003).
OBJECTIVE
To determine response rates and survival times for cats with lymphoma treated with the University of Wisconsin-Madison chemotherapy protocol.


METHODS
Retrospective study.


METHODS
38 cats with lymphoma.


METHODS
Medical records were reviewed, and information on age, sex, breed, FeLV and FIV infection status, anatomic form, clinical stage, and survival time was obtained. Immunophenotyping was not performed.


RESULTS
Mean +/- SD age of the cats was 10.9 +/- 4.4 years. Overall median survival time was 210 days (interquartile range, 90 to 657 days), and overall duration of first remission was 156 days (interquartile range, 87 to 316 days). Age, sex, anatomic form, and clinical stage were not significantly associated with duration of first remission or survival time. Eighteen of the 38 (47%) cats had complete remission, 14 (37%) had partial remission, and 6 (16%) had no response. Duration of first remission was significantly longer for cats with complete remission (654 days) than for cats with partial remission (114 days). Median survival time for cats with complete remission (654 days) was significantly longer than median survival time for cats with partial remission (122 days) and for cats with no response (11 days).


CONCLUSIONS
Results suggested that a high percentage of cats with lymphoma will respond to treatment with the University of Wisconsin-Madison chemotherapy protocol. Age, sex, anatomic form, and clinical stage were not significantly associated with duration of first response or survival time, but initial response to treatment was.
Milner
Rowan J
RJ
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610-0126, USA.
Peyton
Jamie
J
Cooke
Kirsten
K
Fox
Leslie E
LE
Gallagher
Alexander
A
Gordon
Patti
P
Hester
Juli
J
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000401:mortality*; D002415:Cats; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging / Q000662:veterinary; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014922:Wisconsin